REG - C4X Discovery - Block listing Return

C4X Discovery HoldingsAnnouncement

01/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220201:nRSA1986Aa&default-theme=true

RNS Number : 1986A  C4X Discovery Holdings PLC  01 February 2022

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Block Listing Return

 

1 February 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, makes the following notification pursuant to AIM Rule 29
and Schedule Six of the AIM Rules for Companies, regarding its existing block
listing (excluding the additional block listing applications above and those
block listings that have now been cancelled):

 

 Name of applicant:                                                                C4X Discovery Holdings plc
 Name of scheme:                                                                   Warrants
 Period of return:                        From:                                    1 July 2021                 To:                         31 January 2022
 Number and class of share(s) (amount of stock / debt securities) originally       106,964,288 ordinary shares of £0.01 each in the Company admitted to trading
 listed and the date of admission:                                                 on 6 July 2021
 Balance of unallotted securities under scheme(s) from previous return:            106,964,288 ordinary shares
 Plus:  The amount by which the block scheme(s) has been increased since the       Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:        2,200,000
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        104,764,288

 

 Name of contact:              Brad Hoy
 Telephone number of contact:  +44 (0)203 198 0027

 

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early stage novel target
opportunities to late stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRSDIFIFEESEDF